Survodutide vs Retatrutide

Survodutide

Boehringer Ingelheim's investigational GLP-1 / glucagon dual agonist. Phase 2 weight loss in the 15–19% range, with a notable side-effect on liver fibrosis in NASH patients.

Best for

Best if metabolic-liver benefit (MASH/NASH) is central; Survodutide’s glucagon arm targets liver fat directly.

Retatrutide

Triple agonist hitting GIP, GLP-1, and glucagon receptors at once. Phase 2 data shows the largest weight-loss numbers ever reported for a drug in trials — ~24% at 48 weeks.

Best for

Best if maximum weight loss is the goal; the added GIP arm pushes the ceiling higher.

Survodutide

Boehringer Ingelheim's Phase 2 obesity trial (NEJM 2024) showed 14.9–18.7% weight loss at 46 weeks. A separate Phase 2 NASH trial demonstrated liver-fibrosis improvement in roughly 60% of treated patients. Phase 3 (SYNCHRONIZE-1 through 4) is enrolling, covering obesity, cardiovascular outcomes, and NASH. No approval anywhere as of 2026. The dataset is solid for Phase 2 but smaller than Tirzepatide or Semaglutide by orders of magnitude.

Retatrutide

Phase 2 results published in NEJM 2023 showed ~24% weight loss at 12 mg over 48 weeks. The TRIUMPH Phase 3 programme (TRIUMPH-1 through TRIUMPH-4) is enrolling and reporting through 2025–2026, covering obesity, type 2 diabetes, obstructive sleep apnoea, and knee osteoarthritis. No regulatory approval as of mid-2026. The dataset is strong but not yet at the size or duration where rare safety signals would surface.